Aberration of p73 promoter methylation in de novo myelodysplastic syndrome

Hematology

Volumn 17, Issue 5, 2012, Pages 275-282

  Zhao, Youshan ^a   Gu, Shucheng ^a   Guo, Juan ^a   Zhang, Zheng ^a   Zhang, Xi ^a   Li, Xiao ^a   Chang, Chunkang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Decitabine; Hypermethylation; Myelodysplastic syndrome; p73

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; P73 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; BONE MARROW; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA-BINDING PROTEINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84866078903     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000018     Document Type: Article

References (41)

1. Steensma DP, Tefferi A. The myelodysplastic syndrome (s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95-120.
2. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118-129
3. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35:1739-1746.
4. Issa JPJ. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13:1634-1637.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
6. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, et al Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-1325.
7. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819.
8. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, et al p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun. 2005;331:713-717.
9. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, et al p73 in Cancer. Genes Cancer. 2011;2:491-502.
10. Corn GP, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, et al Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associ- ated with 5′ CpG island methylation. Cancer Res. 1999;59:3352.
11. Martinez-Delgado B, Melendez B, Cuadros M, Jose Garcia M, Nomdedeu J, Rivas C, et al Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer. 2002;102:15-9.
12. Sahu GR, Mishra R, Nagpal JK, Das BR. Retracted: alteration of p73 in acute myelogenous leukemia. Am J Hematol. 2005;79:1-7.
13. Ekmekci CG, Gutiérrez MI, Siraj AK, Ozbek U, Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol. 2004;77:233-240.
14. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, et al Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010;5:590.
15. Tamm I, Wagner M, Schmelz K. Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol. 2005;84:47-53.
16. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, et al Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004;104:2492-2498.
17. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, et al DNA methylation of multiple promoter- associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:2217-22124.
18. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol. 2005;23:7043-70439.
19. Siu LLP, Chan JKC, Wong KF, Kwong YL. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol. 2002;160:59.
20. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, et al DNA methylation changes in multiple myeloma. Leukemia 2004;18:1687-16892.
21. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727-736.
22. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079.
24. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419.
25. Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, et al ΔTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 2006;24:805.
26. Chunkang C, Rui Y, Feng X, Juan G, Xi Z, Lingyun W, et al The roles of SDF-1/CXCR4 axis and its relationship with apoptosis in the myelodysplastic syndromes. Med Oncol. 2010:28 Suppl 1:1-7.
27. Christiansen D, Andersen M, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813-1819.
28. Aggerholm A, Holm MS, Guldberg P, Olusen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76: 23-32.
29. Wu X, Liu W, Tian Y, Xiao M, Wu Y, Li C. Aberrant methyl-ation of death-associated protein kinase 1 CpG islands in myelo-dysplastic syndromes. Acta Haematol. 2011;125:179-185.
30. Potapova A, Hasemeier B, Römermann D, Metzig K, Göhrin G, Schlegelberger B, et al Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*. Eur J Haematol. 2010;84:298-303.
31. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG et al A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003;63:1114.
32. Schmelz K, Wagner M, Dörken B, Tamm I. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114:683-695.
33. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23:7594-603.
34. Germing U, Gattermann N, Strupp C, Alvado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983-992.
35. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
36. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Cancer 2007;109:1536-15342.
37. Kantarjian H, Issa JPJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al Decitabine improves patient outcomes in mye-lodysplastic syndromes. Cancer 2006;106:1794-1803.
38. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52-57.
39. Lin J, Yao D, Qian J, Wang YL, Han LX, Jiang YW, et al Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res. 2008;32:1541-1545.
40. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS, et al Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol. 2006;135:317-323.
41. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010; 28:605-613.